Overview

Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This project will investigate the ability of a novel MRI contrast agent to identify and quantitate ongoing monocyte/macrophage (M/MΦ)-mediated inflammation in the brains of HIV-infected individuals.
Phase:
Phase 2
Details
Lead Sponsor:
Beau Nakamoto
Collaborators:
Hawaii Pacific Health
National Institute of Neurological Disorders and Stroke (NINDS)
University of Hawaii
Treatments:
Ferrosoferric Oxide